Context Therapeutics Inc.
CNTXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for CNTX. That does not mean none is planned.
Get an email about CNTX's next catalysts
Track Context Therapeutics (CNTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 2 past
No catalysts found.
Market Overview
Stock performance and key metrics
Extended-release Onapristone
Refractory Endometrial Adenocarcinoma
Onapristone ER
Granulosa Cell Ovarian Cancer
Onapristone ER + Anastrozole
Granulosa Cell Ovarian Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Extended-release Onapristone | Phase 2 | Refractory Endometrial Adenocarcinoma | - | - |
Onapristone ER | Phase 2 | Granulosa Cell Ovarian Cancer | - | - |
Onapristone ER + Anastrozole | Phase 2 | Granulosa Cell Ovarian Cancer | - | - |
Frequently asked questions
What is in Context Therapeutics Inc.'s drug pipeline?β
CatalystAlert tracks 3 drug candidates in Context Therapeutics Inc.'s (CNTX) pipeline across Phase 2. Its lead program is Extended-release Onapristone (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Context Therapeutics Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Context Therapeutics Inc. (CNTX) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track CNTX biotech catalysts?β
Add CNTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Context Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
